Cheng Jing-Ping, Chen Xiang, Chen Jia-Xin
Department of Gerontology, CR & WISCO General Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China.
School of Medicine, Medical College, Wuhan University of Science and Technology, Wuhan, Hubei, China.
Front Med (Lausanne). 2025 Aug 7;12:1549733. doi: 10.3389/fmed.2025.1549733. eCollection 2025.
Sarcopenia is an age-related skeletal muscle disease associated with adverse outcomes such as falls, decreased function, frailty, and death, and is a significant global public health problem that impairs the functioning of individuals. Aging is intensifying, the number of people with sarcopenia is increasing, and there are currently no specific treatment drugs for sarcopenia. The clinical pathogenesis of sarcopenia is extremely complex, and the underlying mechanism of immunosenescence and dysbiosis associated with aging on sarcopenia is not well studied, and they are also potential therapeutic targets for sarcopenia. This review mainly discusses the relationship between sarcopenia from the perspective of intestinal microbiota dysbiosis and T cell changes in immunosenescence, and looks for promising targets for diagnosis or intervention of sarcopenia in the future, hoping to achieve early detection, early diagnosis and early treatment of sarcopenia and prolong the life span of healthy aging.
肌肉减少症是一种与年龄相关的骨骼肌疾病，与跌倒、功能下降、衰弱和死亡等不良后果相关，是一个影响个体功能的重大全球公共卫生问题。老龄化加剧，肌肉减少症患者数量不断增加，目前尚无针对肌肉减少症的特效治疗药物。肌肉减少症的临床发病机制极为复杂，衰老相关的免疫衰老和肠道微生物群失调与肌肉减少症的潜在机制尚未得到充分研究，它们也是肌肉减少症的潜在治疗靶点。本综述主要从肠道微生物群失调和免疫衰老中T细胞变化的角度探讨肌肉减少症之间的关系，并寻找未来肌肉减少症诊断或干预的有前景靶点，希望实现肌肉减少症的早期发现、早期诊断和早期治疗，延长健康衰老的寿命。
